Quantcast
Home > Quotes > MNK

Mallinckrodt plc Ordinary Shares (MNK) Quote & Summary Data

MNK 
$16.11
*  
0.22
1.38%
Get MNK Alerts
*Delayed - data as of May 22, 2018  -  Find a broker to begin trading MNK now
Exchange:NYSE
Industry: Health Care
Community Rating:
View:    MNK Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
15.5
Today's High / Low
$ 16.43 / $ 15.70
Share Volume
1,939,087
90 Day Avg. Daily Volume
3,834,042
Previous Close
$ 15.89
52 Week High / Low
$ 49.12 / $ 11.65
Market Cap
1,338,496,418
P/E Ratio
0.87
Forward P/E (1y)
2.58
Earnings Per Share (EPS)
$ 18.50
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.43

Intraday Chart

Shares Traded

Share Volume:
1,939,087
90 Day Avg. Daily Volume:
3,834,042

P/E Ratio

P/E Ratio:
0.87
Forward P/E (1y):
2.58
Earnings Per Share (EPS):
$ 18.50

Trading Range

The current last sale of $16.11 is 38.28% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 16.43 $ 49.12
 Low: $ 15.70 $ 11.65

Company Description (as filed with the SEC)

We are a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. In the past few years, we have executed on Mallinckrodt's ongoing transformation to become an innovation-driven specialty pharmaceuticals growth company through a series of strategic acquisitions and divestitures, developing strong commercial platforms and an increasingly robust pipeline. In doing so, our emphasis has evolved to focus on a development portfolio of treatments for severe and critically ill infants and adults.  ... More ...  

Risk Grade

Where does MNK fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info